Cargando…

Development and Validation of a New Lymph Node Ratio-Based Staging System for Ampullary Carcinoma After Curative Pancreaticoduodenectomy

BACKGROUND: Lymph node metastasis (LNM) is closely associated with the prognosis of ampullary carcinoma (AC). The purpose of this study is to explore the relationship between lymph node ratio (LNR) and the prognosis of patients with AC after curative pancreaticoduodenectomy and to establish a new LN...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaojie, Sun, Chongyuan, Li, Zefeng, Wang, Tongbo, Zhao, Lulu, Niu, Penghui, Guo, Chunguang, Chen, Yingtai, Che, Xu, Zhao, Dongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810493/
https://www.ncbi.nlm.nih.gov/pubmed/35127524
http://dx.doi.org/10.3389/fonc.2021.811595
_version_ 1784644265456959488
author Zhang, Xiaojie
Sun, Chongyuan
Li, Zefeng
Wang, Tongbo
Zhao, Lulu
Niu, Penghui
Guo, Chunguang
Chen, Yingtai
Che, Xu
Zhao, Dongbing
author_facet Zhang, Xiaojie
Sun, Chongyuan
Li, Zefeng
Wang, Tongbo
Zhao, Lulu
Niu, Penghui
Guo, Chunguang
Chen, Yingtai
Che, Xu
Zhao, Dongbing
author_sort Zhang, Xiaojie
collection PubMed
description BACKGROUND: Lymph node metastasis (LNM) is closely associated with the prognosis of ampullary carcinoma (AC). The purpose of this study is to explore the relationship between lymph node ratio (LNR) and the prognosis of patients with AC after curative pancreaticoduodenectomy and to establish a new LNR-based staging system. METHODS: AC patients in the Cancer Hospital, Chinese Academy of Medical Sciences, between 1998 and 2020 were retrospectively reviewed as the training cohort; and AC patients in the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2018 were obtained as the validation cohort. Within the training group, Kaplan–Meier survival analyses and Cox proportional hazards regression were conducted to assess the prognostic value of LNR and establish a new LNR-based staging system. Then, the new staging system was compared with the 8th American Joint Committee on Cancer (AJCC) TNM staging system in both the training and validation cohorts. RESULTS: A total of 264 patients in the training cohort and 199 patients in the validation cohort were enrolled. Significant overall survival (OS) difference was observed between LNR-low stage and LNR-high stage in both training (p = 0.001) and validation cohorts (p < 0.001). Then a new LNR-based staging system was developed. Under the new system, the number of patients in the training cohort and validation cohort of stage I, stage II, and stage III was 30 (11%) vs. 18 (9%), 190 (72%) vs. 96 (48%), and 44 (17%) vs. 85 (43%), respectively. The new staging system classified patients with respect to survival better than did the 8th AJCC TNM staging system. CONCLUSIONS: The new LNR-based staging system had better discriminability for predicting survival in AC patients after curative pancreaticoduodenectomy. More data are needed for further validation.
format Online
Article
Text
id pubmed-8810493
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88104932022-02-04 Development and Validation of a New Lymph Node Ratio-Based Staging System for Ampullary Carcinoma After Curative Pancreaticoduodenectomy Zhang, Xiaojie Sun, Chongyuan Li, Zefeng Wang, Tongbo Zhao, Lulu Niu, Penghui Guo, Chunguang Chen, Yingtai Che, Xu Zhao, Dongbing Front Oncol Oncology BACKGROUND: Lymph node metastasis (LNM) is closely associated with the prognosis of ampullary carcinoma (AC). The purpose of this study is to explore the relationship between lymph node ratio (LNR) and the prognosis of patients with AC after curative pancreaticoduodenectomy and to establish a new LNR-based staging system. METHODS: AC patients in the Cancer Hospital, Chinese Academy of Medical Sciences, between 1998 and 2020 were retrospectively reviewed as the training cohort; and AC patients in the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2018 were obtained as the validation cohort. Within the training group, Kaplan–Meier survival analyses and Cox proportional hazards regression were conducted to assess the prognostic value of LNR and establish a new LNR-based staging system. Then, the new staging system was compared with the 8th American Joint Committee on Cancer (AJCC) TNM staging system in both the training and validation cohorts. RESULTS: A total of 264 patients in the training cohort and 199 patients in the validation cohort were enrolled. Significant overall survival (OS) difference was observed between LNR-low stage and LNR-high stage in both training (p = 0.001) and validation cohorts (p < 0.001). Then a new LNR-based staging system was developed. Under the new system, the number of patients in the training cohort and validation cohort of stage I, stage II, and stage III was 30 (11%) vs. 18 (9%), 190 (72%) vs. 96 (48%), and 44 (17%) vs. 85 (43%), respectively. The new staging system classified patients with respect to survival better than did the 8th AJCC TNM staging system. CONCLUSIONS: The new LNR-based staging system had better discriminability for predicting survival in AC patients after curative pancreaticoduodenectomy. More data are needed for further validation. Frontiers Media S.A. 2022-01-20 /pmc/articles/PMC8810493/ /pubmed/35127524 http://dx.doi.org/10.3389/fonc.2021.811595 Text en Copyright © 2022 Zhang, Sun, Li, Wang, Zhao, Niu, Guo, Chen, Che and Zhao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Xiaojie
Sun, Chongyuan
Li, Zefeng
Wang, Tongbo
Zhao, Lulu
Niu, Penghui
Guo, Chunguang
Chen, Yingtai
Che, Xu
Zhao, Dongbing
Development and Validation of a New Lymph Node Ratio-Based Staging System for Ampullary Carcinoma After Curative Pancreaticoduodenectomy
title Development and Validation of a New Lymph Node Ratio-Based Staging System for Ampullary Carcinoma After Curative Pancreaticoduodenectomy
title_full Development and Validation of a New Lymph Node Ratio-Based Staging System for Ampullary Carcinoma After Curative Pancreaticoduodenectomy
title_fullStr Development and Validation of a New Lymph Node Ratio-Based Staging System for Ampullary Carcinoma After Curative Pancreaticoduodenectomy
title_full_unstemmed Development and Validation of a New Lymph Node Ratio-Based Staging System for Ampullary Carcinoma After Curative Pancreaticoduodenectomy
title_short Development and Validation of a New Lymph Node Ratio-Based Staging System for Ampullary Carcinoma After Curative Pancreaticoduodenectomy
title_sort development and validation of a new lymph node ratio-based staging system for ampullary carcinoma after curative pancreaticoduodenectomy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810493/
https://www.ncbi.nlm.nih.gov/pubmed/35127524
http://dx.doi.org/10.3389/fonc.2021.811595
work_keys_str_mv AT zhangxiaojie developmentandvalidationofanewlymphnoderatiobasedstagingsystemforampullarycarcinomaaftercurativepancreaticoduodenectomy
AT sunchongyuan developmentandvalidationofanewlymphnoderatiobasedstagingsystemforampullarycarcinomaaftercurativepancreaticoduodenectomy
AT lizefeng developmentandvalidationofanewlymphnoderatiobasedstagingsystemforampullarycarcinomaaftercurativepancreaticoduodenectomy
AT wangtongbo developmentandvalidationofanewlymphnoderatiobasedstagingsystemforampullarycarcinomaaftercurativepancreaticoduodenectomy
AT zhaolulu developmentandvalidationofanewlymphnoderatiobasedstagingsystemforampullarycarcinomaaftercurativepancreaticoduodenectomy
AT niupenghui developmentandvalidationofanewlymphnoderatiobasedstagingsystemforampullarycarcinomaaftercurativepancreaticoduodenectomy
AT guochunguang developmentandvalidationofanewlymphnoderatiobasedstagingsystemforampullarycarcinomaaftercurativepancreaticoduodenectomy
AT chenyingtai developmentandvalidationofanewlymphnoderatiobasedstagingsystemforampullarycarcinomaaftercurativepancreaticoduodenectomy
AT chexu developmentandvalidationofanewlymphnoderatiobasedstagingsystemforampullarycarcinomaaftercurativepancreaticoduodenectomy
AT zhaodongbing developmentandvalidationofanewlymphnoderatiobasedstagingsystemforampullarycarcinomaaftercurativepancreaticoduodenectomy